# MTAPESTRY 101 (NCT05094336)

> A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

No report yet. It can be ordered.

- Drugs tested: anvumetostat (AMG 193); anvumetostat (AMG 193) plus docetaxel
- Indication: advanced MTAP-null solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05094336
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Advanced MTAP-null Solid Tumors
- Interventions: Anvumetostat; Docetaxel; Comparator Anvumetostat Test Tablet
- Enrollment: 329
- Primary outcome: Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Primary outcome: Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
- Primary outcome: Part 3: Objective Response Rate (ORR)

## Indexed commentary on MTAPESTRY 101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mtapestry-101-nct05094336